RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

Benzinga · 4d ago
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $296 to $305.